Browsing Clinical Studies by author "Bliss, Judith"
Now showing items 21-40 of 94
-
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner, NC; Kingston, B; Kilburn, LS; Kernaghan, S; Wardley, AM; et al. (ELSEVIER SCIENCE INC, 2020-10-01)BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing ... -
Clinical Trials From the Other Side: Lessons Learned by a Clinician Venturing Into a Clinical Trials Unit.
Bhattacharya, IS; Bliss, JM (ELSEVIER SCIENCE LONDON, 2019-07) -
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Bliss, JM; Tovey, H; Evans, A; Holcombe, C; Horgan, K; et al. (BMC, 2023-04-12)PURPOSE: Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with ... -
Combined Peri-operative Lapatinib and Trastuzumab in Early HER2 Positive Breast Cancer can Identify Early Responders: Results from the UK EPHOS-B Trial (CRUK/08/002
Bliss, J; Porta, N; Emson, M; Miller, S; Morden, J (American Association for Cancer Research, 2022-04-01) -
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Bundred, N; Porta, N; Brunt, AM; Cramer, A; Hanby, A; et al. (AMER ASSOC CANCER RESEARCH, 2022-04-01)PURPOSE: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. PATIENTS AND METHODS: This randomized phase II, two-part, ... -
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
Hall, E; Cameron, D; Waters, R; Barrett-Lee, P; Ellis, P; et al. (ELSEVIER SCI LTD, 2014-09-01)BACKGROUND: The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results at a ... -
Conducting non-commercial international clinical trials: the ICR-CTSU experience.
Fox, L; Toms, C; Kernaghan, S; Snowdon, C; Bliss, JM (BMC, 2017-09-26)BACKGROUND: Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly ... -
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
Glynn, D; Bliss, J; Brunt, AM; Coles, CE; Wheatley, D; et al. (SPRINGER, 2022-11-17)PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) ... -
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Szijgyarto, Z; Flach, KD; Opdam, M; Palmieri, C; Linn, SC; et al. (SPRINGER, 2019-05-01)PURPOSE: The prognostic and predictive values of the MAPK/AKT/ERα phosphorylation axis (pT202/T204MAPK, pT308AKT, pS473AKT, pS118ERα and pS167ERα) in primary tumours were assessed to determine whether these markers can ... -
Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
Haviland, JS; Hopwood, P; Mills, J; Sydenham, M; Bliss, JM; et al. (ELSEVIER SCIENCE LONDON, 2016-06-01)AIMS: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data ... -
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Coles, CE; Haviland, JS; Kirby, AM; Griffin, CL; Sydenham, MA; et al. (ELSEVIER SCIENCE INC, 2023-06-24)BACKGROUND: A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast hardness. IMPORT HIGH tested simultaneous integrated ... -
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
O'Leary, B; Hrebien, S; Morden, JP; Beaney, M; Fribbens, C; et al. (NATURE PORTFOLIO, 2018-03-01)CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA ... -
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Coombes, RC; Tovey, H; Kilburn, L; Mansi, J; Palmieri, C; et al. (AMER MEDICAL ASSOC, 2021-09-01)IMPORTANCE: Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. OBJECTIVE: To ... -
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.
Goodwin, PJ; Chen, BE; Gelmon, KA; Whelan, TJ; Ennis, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-12-10)Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not ... -
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Goodwin, PJ; Chen, BE; Gelmon, KA; Whelan, TJ; Ennis, M; et al. (AMER MEDICAL ASSOC, 2022-05-24)IMPORTANCE: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. OBJECTIVE: To determine ... -
Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
Coombes, RC; Kilburn, LS; Tubiana-Mathieu, N; Olmos, T; Van Bochove, A; et al. (ELSEVIER SCI LTD, 2016-06-01)BACKGROUND: The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node ... -
Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting.
Patel, D; Kilburn, L; Fox, L; Hall, E; Bliss, J; et al. (BMC, 2023-11-28)BACKGROUND: Clinical trials should be as inclusive as possible to facilitate equitable access to research and better reflect the population towards which any intervention is aimed. Informed by the UK's National Institute ... -
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
Castelo-Branco, L; Pellat, A; Martins-Branco, D; Valachis, A; Derksen, JWG; et al. (ELSEVIER, 2023-10-15) -
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.
Turner, NC; Swift, C; Kilburn, L; Fribbens, C; Beaney, M; et al. (AMER ASSOC CANCER RESEARCH, 2020-10-01)PURPOSE: ESR1 mutations are acquired frequently in hormone receptor-positive metastatic breast cancer after prior aromatase inhibitors. We assessed the clinical utility of baseline ESR1 circulating tumor DNA (ctDNA) analysis ... -
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang, MCU; Bliss, JM; Viale, G; Speirs, V; Palmieri, C; et al. (SPRINGER, 2018-02-01)BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the ...